Clinical Trial

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated March 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.
Trial Details
NCT Number NCT06514118
Lead Sponsor Qingdao Central Hospital
Conditions Small-cell Lung Cancer, Residual Tumor, Radiation
Enrollment 70 participants
Start Date 2024-04-17
Primary Completion 2026-03-16 (estimated)
Study Completion 2027-03-16 (estimated)
Updated on ClinicalTrials.gov 2024-07-23